Publications

Research  Area
Reforming policy on private Drug Rehabilitation Centres: Addressing Gaps and Proposing Solutions for Better Treatment Outcomes.
Journal: International Journal of Drug Policy

Under Review

Report Name: Annual Drug Report of Bangladesh (DNC)

Department of Narcotics Control (DNC), Government of Bangladesh publishes the Annual Drug Report of Bangladesh, which presents yearly highlights of national drug control activities, prevention initiatives, and institutional updates.

Reports (Official):

1. Department of Narcotics Control (DNC). (2022). Annual Drug Report of Bangladesh, 2022. Dhaka, Bangladesh.

2. Department of Narcotics Control (DNC). (2020). Annual Drug Report of Bangladesh, 2020. Dhaka, Bangladesh.

3. Department of Narcotics Control (DNC). (2020–2021). Annual Report 2020–2021. Dhaka, Bangladesh.
   
   

More publications and annual reports: DNC Annual Reports archive.

Manuscripts Under Review

Dey, U. (under review). A qualitative research on post-rehabilitation mental stress and drug relapse [use exact submitted title]. Global Mental Health.

Preprints

Dey, U., & Hasain, M. (2026). Punishing with walls, neglecting with silence: Structural gaps and clinical blindness in Bangladesh’s rehabilitation regulations [Preprint]. Research Square. https://doi.org/10.21203/rs.3.rs-10388828/v1

Professional and Public Writing

Dey, U. (2026). The Invisible Crisis: Female Substance Use Disorder, Psychological Trauma, and Policy Gaps in Bangladesh [Substance use disorder and psychological trauma among women]. Global Recovery Network.

Dey, U. (2026). Using Digital Innovation to Treat Substance Use in Bangladesh [Digital innovation in substance use treatment in Bangladesh]. The Global Women’s Network.

Dey, U. (2026). Hooked all day: Is it time for Bangladesh to rejig its rehabilitation policies on mobile addiction in children?[Mobile addiction among children]. Dhaka Tribune.

Policy Reference (Relevant National Document)

Government of Bangladesh. (2016). National Drug Policy, 2016. This policy outlines the national framework for regulated drug management and aligns with broader public health priorities.